| Analysis | Samples | Factors | Units |
|---|---|---|---|
| Reversed phase UNSPECIFIED ION MODE | BM_FFA_1 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | BM_FFA_2 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | BM_FFA_3 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | BM_FFA_4 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | BM_Oxylipin_1 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | BM_Oxylipin_2 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | BM_Oxylipin_3 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | BM_Oxylipin_4 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | CO_FFA_1 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | CO_FFA_2 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | CO_FFA_3 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | CO_FFA_4 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | CO_Oxylipin_1 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | CO_Oxylipin_2 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | CO_Oxylipin_3 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | CO_Oxylipin_4 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | PL_FFA_1 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | PL_FFA_2 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | PL_FFA_3 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | PL_FFA_4 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | PL_Oxylipin_1 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | PL_Oxylipin_2 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | PL_Oxylipin_3 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | PL_Oxylipin_4 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | SP_FFA_1 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | SP_FFA_2 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | SP_FFA_3 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | SP_FFA_4 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | SP_Oxylipin_1 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | SP_Oxylipin_2 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | SP_Oxylipin_3 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | SP_Oxylipin_4 | Genotype:Wild-type | Treatment:LPS | intensity |
| Reversed phase UNSPECIFIED ION MODE | BM_FFA_5 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | BM_FFA_6 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | BM_FFA_7 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | BM_FFA_8 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | BM_Oxylipin_5 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | BM_Oxylipin_6 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | BM_Oxylipin_7 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | BM_Oxylipin_8 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | CO_FFA_5 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | CO_FFA_6 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | CO_FFA_7 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | CO_FFA_8 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | CO_Oxylipin_5 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | CO_Oxylipin_6 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | CO_Oxylipin_7 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | CO_Oxylipin_8 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | PL_FFA_5 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | PL_FFA_6 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | PL_FFA_7 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | PL_FFA_8 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | PL_Oxylipin_5 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | PL_Oxylipin_6 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | PL_Oxylipin_7 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | PL_Oxylipin_8 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | SP_FFA_5 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | SP_FFA_6 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | SP_FFA_7 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | SP_FFA_8 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | SP_Oxylipin_5 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | SP_Oxylipin_6 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | SP_Oxylipin_7 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
| Reversed phase UNSPECIFIED ION MODE | SP_Oxylipin_8 | Genotype:Wild-type | Treatment:LPS+antiPla2g5 | intensity |
Return to study ST002455 main page
Download data matrix(Organism-Wide Analysis of Sepsis Reveals Mechanisms of Systemic Inflammation Reversed phase UNSPECIFIED ION MODE)
- Metabolomics Workbench
|